Prostate Health Archive

Prostatitis (infection or inflammation of the prostate gland) flies under the radar even though it affects up to one in six men at some point in their lifetimes. It triggers more than two million visits to doctors and untold agony each year.

Radical prostatectomy changes the experience of orgasm. But it doesn’t need to be any less pleasurable or satisfying, says Dr. Ravi Kacker, a urologist and fellow in male sexual medicine at Harvard-affiliated Beth Israel Deaconess Medical Center.

New research has has identified an enzyme that may be the escape hatch that advanced prostate cancer uses to evade hormone therapy. If the findings hold up, the enzyme might be a prime target for a drug that would treat castration-resistant prostate cancer.

Metformin—the drug that millions of people with diabetes take to control their blood sugar—may be on the brink of a second career. Evidence from a variety of studies suggests that metformin may delay or slow the progression of prostate cancer. Metformin does not, however, appear to prevent the development of prostate cancer in the first place.

In many men diagnosed with prostate cancer, the cancer cells grow so slowly that they never break free of the gland, spread to distant sites, and pose a serious risk to health and longevity. Instead of embarking on immediate treatment, a growing number of men choose active surveillance, in which doctors monitor low-risk cancers closely and consider treatment only when the disease appears to make threatening moves toward growing and spreading. A new Harvard study shows that the aggressiveness of prostate cancer at diagnosis remains stable over time for most men. If confirmed, then prompt treatment can be reserved for the cancers most likely to pose a threat, while men with slow-growing, benign prostate cancer—which is unlikely to cause problems in a man’s lifetime—can reasonably choose active surveillance.

The omega-3 fats in fish have been linked to all sorts of health benefits, including protection against prostate cancer. But for the second time in two years, researchers have found a link between high levels of omega-3 fats in the blood and prostate cancer. Researchers at the Fred Hutchinson Cancer Center in Seattle men with high levels of omega-3 fats were 43% more likely to have been diagnosed with prostate cancer than men with low levels. The finding were published online in the Journal of the National Cancer Institute.

The radioactive element radium has been used to treat cancer since soon after its discovery in 1898 by Marie Curie and her husband, Pierre. And it’s still finding new uses—a recently approved form of radium, radium-223 (Xofigo), is now being used to treat prostate cancer that has spread to the bones. Researchers say that Xofigo addresses “an unmet need” in men with this type of prostate cancer, since current therapies don’t work very well against it.

Is it possible for a gene test to identify whether a prostate that’s healthy today is sure to develop cancer down the road? And should results of such a test be the basis for removing a seemingly healthy prostate gland? Those are questions raised by recent press reports of a British man who had his prostate gland removed because he carried a faulty gene called BRCA2.

Each year, nearly a quarter of a million American men learn they have prostate cancer. Most are diagnosed with early-stage cancer that has not spread beyond the prostate gland. Traditional treatments include surgery, radiation therapy, and a “watch and wait” strategy called active surveillance. A new study published online this week in JAMA Internal Medicine indicates that diet may be an important add-on. The study, part of the ongoing Harvard-based Health Professionals Follow-up Study, suggests that eating more foods that deliver healthy vegetable oils can help fight the second leading cause of cancer death in men. Earlier studies have implicated the traditional Western diet, which is relatively high in red meat and other sources of animal fats, with a higher risk for developing prostate cancer in the first place, while eating more vegetable oils and vegetable protein may help prevent it.

The FDA has approved a new kind of PSA test for prostate cancer that its maker claims can help doctors do a better job of telling the difference between prostate cancer and less worrisome conditions such as prostate infection or benign prostate enlargement. The test, called the Prostate Health Index (PHI), should become available in the U.S. later this summer. The PHI combines measurements of three kinds of prostate specific antigen (PSA), a protein produced by the prostate gland. In theory, the combination could help reduce the number of men who undergo prostate biopsies when their PSA levels are slightly above normal, in the 4 to 10 nanogram per milliliter range. But doctors must take care not to allow use of the PHI test to worsen the existing overdiagnosis and overtreatment of low-risk cancers, according to Dr. Marc B. Garnick, an expert in prostate cancer at Harvard Medical School and editor in chief of HarvardProstateKnowledge.org.